Search Within

Neeta Pandit-Taskar

  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (51)
  2. Meeting Abstract (44)
  3. Review (1)
Groups
  1. Department of Medicine (96)
  2. Molecular Imaging and Therapy Service (96)
  3. Radiology, Department of (96)
  4. Solid Tumor Oncology Division (96)
  5. GSK Faculty (67)
  6. Genitourinary Oncology Service (52)

More Groups

People
  1. Steven Larson (46)
  2. Michael Morris (45)
  3. Joseph O'Donoghue (44)
  4. Jorge Carrasquillo (40)
  5. Howard Scher (32)
  6. Serge Lyashchenko (30)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (3)
  4. 2022 (8)
  5. 2021 (4)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (31)
  2. Journal of Nuclear Medicine (22)
  3. Clinical Cancer Research (8)
  4. European Journal of Nuclear Medicine and Molecular Imaging (7)
  5. Journal for ImmunoTherapy of Cancer (3)
  6. Cancer Research (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (31)
  2. Society of Nuclear Medicine (22)
  3. Springer (13)
  4. American Association for Cancer Research (12)
  5. Elsevier Inc. (7)
  6. Biomed Central Ltd (3)

More Publishers

Results (96)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using (18)F-BMS-986229 PET
    Meeting Abstract

    Cytryn, S. L.; Pandit-Taskar, N.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Feder, L.; Philemond, S.; Lyashchenko, S. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 0 study to assess the biodistribution and pharmacokinetics of a radiolabeled antibody targeting human kallikrein 2 in participants with metastatic castration-resistant prostate cancer
    Journal Article

    Pandit-Taskar, N.; O'Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Ilovich, O.; Russell, M.; Nyima, T.; Divgi, C. R.; Yu, M.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • (18)F-BMS-986229 PET to assess programmed-death ligand 1 status in gastroesophageal cancer
    Journal Article

    Cytryn, S. L.; Pandit-Taskar, N.; Lumish, M. A.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Antoine, A.; Loegel, D.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: A pilot study
    Journal Article

    Lumish, M. A.; Maron, S. B.; Paroder, V.; Chou, J. F.; Capanu, M.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Lyashchenko, S. K.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Assessing the correlation between CD8 cell PET imaging with 89-ZR-crefmirlimab berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy
    Meeting Abstract

    Postow, M.; Mauguen, A.; Farwell, M.; Gordon, M.; Hays, D.; Wong, J.; Pal, S.; Chen, D.; Ulaner, G.; McConathy, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Assessing PD-L1 without a biopsy and through PD-L1 PET imaging with 18F-BMS-986229
    Meeting Abstract

    Postow, M. A.; Mauguen, A.; Frosina, D.; Jungbluth, A. A.; Busam, K. J.; Pandit Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer
    Meeting Abstract

    Morris, M. J.; Sartor, A. O.; Wong, J. Y. C.; Max, S. I.; Xie, H.; Yu, A.; Divgi, C. R.; Patricia, D.; Avadhani, A. N.; Pandit-Taskar, N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save